Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.33% |
| 2 | Healthcare | 16.97% |
| 3 | Consumer Discretionary | 12.86% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2326
TAT Technologies
TATT
$543M
| $1.25M | ﹤0.01% |
168,430
-2,372
| -1% | -$15K |
|
|
CLCO
2327
DELISTED
Cool Company
CLCO
| $1.25M | ﹤0.01% |
+91,894
| New | +$1.15M |
|
2328
Sutro Biopharma
STRO
$352M
| $1.25M | ﹤0.01% |
26,950
+14,010
| +108% | +$697K |
|
2329
Allogene Therapeutics
ALLO
$694M
| $1.25M | ﹤0.01% |
251,900
-176,800
| -41% | -$956K |
|
2330
Northrim BanCorp
NRIM
$607M
| $1.25M | ﹤0.01% |
127,200
-6,800
| -5% | -$68.3K |
|
2331
Transportadora de Gas del Sur
TGS
$4.22B
| $1.25M | ﹤0.01% |
+90,361
| New | +$1.09M |
|
|
VBTX
2332
DELISTED
Veritex Holdings
VBTX
| $1.24M | ﹤0.01% |
+69,225
| New | +$1.23M |
|
2333
STRATTEC Security
STRT
$341M
| $1.24M | ﹤0.01% |
68,206
+100
| +0.1% | +$1.91K |
|
2334
State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF
SPTM
$14.1B
| $1.24M | ﹤0.01% |
+22,700
| New | +$1.17M |
|
2335
AC Immune
ACIU
$247M
| $1.24M | ﹤0.01% |
417,979
+6,900
| +2% | +$15.1K |
|
2336
Century Casinos
CNTY
$35.2M
| $1.23M | ﹤0.01% |
173,849
+11,500
| +7% | +$81.6K |
|
2337
Halozyme
HALO
$11.2B
| $1.23M | ﹤0.01% |
34,080
-61,061
| -64% | -$2.08M |
|
2338
Heron Therapeutics
HRTX
$63.4M
| $1.23M | ﹤0.01% |
1,059,100
-81,736
| -7% | -$146K |
|
|
TVRD
2339
Tvardi Therapeutics
TVRD
$24.4M
| $1.23M | ﹤0.01% |
12,057
+11,069
| +1,120% | +$1.52M |
|
|
LITB
2340
LightInTheBox
LITB
$53.8M
| $1.23M | ﹤0.01% |
173,355
+2,058
| +1% | +$16.2K |
|
|
HIBB
2341
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $1.23M | ﹤0.01% |
33,788
-29,000
| -46% | -$1.39M |
|
2342
Taylor Devices
TAYD
$172M
| $1.22M | ﹤0.01% |
47,662
+2,100
| +5% | +$44.3K |
|
2343
BJ's Restaurants
BJRI
$1.42B
| $1.22M | ﹤0.01% |
38,229
-92,800
| -71% | -$2.83M |
|
2344
CBIZ
CBZ
$2.96B
| $1.22M | ﹤0.01% |
22,826
+12,826
| +128% | +$660K |
|
2345
Coastal Financial
CCB
$775M
| $1.21M | ﹤0.01% |
32,207
-2,567
| -7% | -$91.7K |
|
2346
iShares Core S&P Total US Stock Market ETF
ITOT
$98.4B
| $1.21M | ﹤0.01% |
12,400
+9,500
| +328% | +$878K |
|
2347
Pulmonx
LUNG
$97.5M
| $1.21M | ﹤0.01% |
92,400
-102,445
| -53% | -$1.25M |
|
2348
Pampa Energía
PAM
$4.22B
| $1.21M | ﹤0.01% |
27,953
-29,507
| -51% | -$1.09M |
|
2349
abrdn Physical Silver Shares ETF
SIVR
$4.53B
| $1.21M | ﹤0.01% |
55,300
-34,500
| -38% | -$801K |
|
2350
Standard BioTools
LAB
$291M
| $1.21M | ﹤0.01% |
625,309
+289,009
| +86% | +$570K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.